[ NeuroVia raises $14M in Series A ]
NeuroVia has raised $14 million in Series A funding.
Founded in 2013, NeuroVia is committed to addressing unmet medical needs in neurological diseases with the primary goal to arrest the onset of devastating neurological deficits associated with X-ALD.
The funding will support the advance of the company’s lead candidate, NV1205, into a clinical proof-of-concept development program in X-linked adrenoleukodystrphy (X-ALD).
|City||San Francisco, California|
|Founder / CEO||Giovanni Ferrara|
|Novartis Venture Fund|